MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges. (2024)
Attributed to:
Targeting natural killer cell receptors for immunotherapeutic benefit
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers16020259
PubMed Identifier: 38254750
Publication URI: http://europepmc.org/abstract/MED/38254750
Type: Journal Article/Review
Volume: 16
Parent Publication: Cancers
Issue: 2
ISSN: 2072-6694